Julia Morawski

Senior Director, Access And HEOR Strategy at Intellia Therapeutics

Julia Morawski has extensive experience in the field of healthcare and pharmaceuticals. Julia is currently working as the Senior Director of Access and HEOR Strategy at Intellia Therapeutics, Inc. Prior to this, they held the position of Director of Health Economics and Outcomes Research at Vertex Pharmaceuticals from July 2018 to November 2021. Before that, they worked at Sanofi Genzyme as the Director of Health Economics and Value Assessment from September 2017 to July 2018, and as the Associate Director of Health Economics and Value Assessment from September 2015 to September 2017. Julia also has experience at Quintiles, where they worked as a Market Access Consultant from September 2013 to September 2015, and as a Market Access Consulting Analyst from April 2011 to April 2013. Julia has also held roles at Novartis Vaccines and Diagnostics as a TMF Lead in March 2011, and at Genzyme Europe B.V as a Clinical Research Coordinator from January 2009 to March 2011. Prior to that, Julia worked as a Data Entry Assistant at Medtronic/EMC from December 2008 to February 2009. Julia began their career as an Intern at OctoPlus N.V, where they worked as a Market Research Analyst from September 2007 to January 2008. Julia also gained research experience as a Research Assistant in Experimental Oncology at Utrecht, The Netherlands from October 2005 to June 2006. Overall, their work experience demonstrates their expertise in various aspects of health economics, outcomes research, and market access.

Julia Morawski obtained their Master's degree in Cancer Genomics and Developmental Biology with a Minor in Business Management from Utrecht University during the period of 2005 to 2008. Their education focused on Cancer & Stem Cell research, biomedical & biomolecular science, marketing, economics, and management.

Links

Previous companies

Novartis logo
IQVIA logo
Sanofi logo
Vertex Pharmaceuticals logo

Org chart

Timeline

  • Senior Director, Access And HEOR Strategy

    January, 2022 - present

View in org chart